The paradigm shift from <scp>NAFLD</scp> to <scp>MAFLD</scp>: A global primary care viewpoint

Farahat, Taghreed M; Ungan, Mehmet; Vilaseca, Josep; Ponzo, Jacqueline; Gupta, P. P.; Schreiner, Andrew D.; Sharief, Wadeia Al; Casler, Kelly; Abdelkader, Tafat; Abenavoli, Ludovico; Alami, Fatima-Zohra Mchich; Ekstedt, Mattias; Jabir, Muntadar Saad; Armstrong, Matthew J.; Hage, Mona Osman El; Attia, Dina; Verhoeven, Véronique; Amir, Ashraf; Hegazy, Nagwa N; Tsochatzis, Emmanuel; Fouad, Yasser; Cortez‐Pinto, Helena

doi:10.1111/liv.15188

Cited by 17 publications

(18 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30 Additionally, some experts have defined a new term known as metabolic dysfunction-associated fatty liver disease (MAFLD). 30 MAFLD is defined as the presence of histological, imaging, or blood biomarker evidence of hepatic steatosis in addition to the presence of one of the following conditions: namely, overweight or obese, type 2 diabetes mellitus, and evidence of metabolic dysregulation. 18 The evidence of metabolic dysregulation in the definition of MAFLD is relatively similar to the criteria previously defined for metabolic syndrome.…”

Section: Nafld Is a Component Of Metabolic Syndromementioning

confidence: 99%

Section: Nafld Is a Component Of Metabolic Syndromementioning

confidence: 99%

“…Because of its association with metabolic syndrome, common etiologies, and complications, NAFLD is often considered the hepatic component of metabolic syndrome 30 . Additionally, some experts have defined a new term known as metabolic dysfunction‐associated fatty liver disease (MAFLD) 30 . MAFLD is defined as the presence of histological, imaging, or blood biomarker evidence of hepatic steatosis in addition to the presence of one of the following conditions: namely, overweight or obese, type 2 diabetes mellitus, and evidence of metabolic dysregulation 18 …”

Section: Nafld Is a Component Of Metabolic Syndromementioning

confidence: 99%

See 2 more Smart Citations

Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: A clinical and epidemiological perspective

Ala

Eftekhar

2023

Obesity Reviews

View full text Add to dashboard Cite

Summary Nonalcoholic fatty liver disease (NAFLD) is a growing health concern that is closely related to obesity and metabolic syndrome. In particular, NAFLD has been increasingly reported in adolescents and young adults in recent years. Cardiovascular diseases (CVDs) such as cardiac remodeling, heart failure, myocardial infarction, valvular heart diseases, and arrhythmia are more common in patients with NAFLD. CVD are the major cause of mortality in NAFLD. Although NAFLD often affects patients with obesity/overweight, it can also affect subjects with normal body mass index (BMI), known as lean NAFLD, which has a strong correlation with CVD. Obesity imposes a considerably increased risk of NAFLD and CVD. Consistently, weight‐lowering approaches that can pronouncedly decrease body weight and maintain it in the long term, such as bariatric surgery and treatment with semaglutide and tirzepatide, have been promising in alleviating both CVD and NAFLD. Interestingly, compared with patients with NAFLD and obesity, a minimal amount of weight loss resolves NAFLD in lean patients. Besides the widespread use of bariatric surgery, the development of new GLP‐1 agonists and GLP‐1 GIP agonists revolutionized the treatment of obesity in recent years. Here, we discuss the interwoven correlation between obesity, NAFLD, and CVD and the benefits of weight‐lowering approaches.

show abstract

Section: Nafld Is a Component Of Metabolic Syndromementioning

confidence: 99%

Section: Nafld Is a Component Of Metabolic Syndromementioning

confidence: 99%

Section: Nafld Is a Component Of Metabolic Syndromementioning

confidence: 99%

See 1 more Smart Citation

Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: A clinical and epidemiological perspective

Ala

Eftekhar

2023

Obesity Reviews

View full text Add to dashboard Cite

show abstract

“…NAFLD is the most common cause of chronic liver disease and is estimated to have affected a quarter of the global population (31, 32). Of note, given the role of cardiometabolic risk factors in the development and progression of the disease, two new position papers (29, 30) proposed the terminology of MAFLD instead of NAFLD in 2020 to better capture the pathophysiology of the disease (33,34).…”

Section: Introductionmentioning

confidence: 99%

COVID-19 and MAFLD/NAFLD: An updated review

2023

View full text Add to dashboard Cite

The COVID-19 pandemic is ongoing and places a substantial burden on healthcare systems worldwide. As we further shed light on different disease characteristics, we identify more and more groups of people at higher risk of poor COVID-19 outcomes. Metabolic-associated fatty liver disease (MAFLD) (previously non-alcoholic fatty liver disease or NAFLD) is a common metabolic disorder characterized by fat accumulation and liver fibrosis. Given its close correlation with metabolic syndrome, an established risk factor for severe COVID-19, it is necessary to investigate its interplay with the novel coronavirus. In this study, we review the available data on COVID-19 prognosis, treatment and prevention options in patients with MAFLD, and the effect that the disease and the pandemic have on MAFLD care. Furthermore, we point out the gaps in the current literature to accentuate the work that needs to be done to improve MAFLD care during the pandemic and beyond.

show abstract

“…The other positive attribute of the MAFLD criteria is that it can be easily incorporated into standard healthcare packages which would then improve in its detection, particularly in the primary care setting, and allow for efficient referral and management. 9 , 10 …”

mentioning

confidence: 99%